3 hrs ago
Glaxo CEO Witty to focus on 'key franchises' instead of smaller money makers
When the asset swap between GlaxoSmithKline , Novartis and Eli Lilly goes through in the first part of next year, each company says it will generate a larger portion of its overall revenue from its key focus areas.
Trending on the Topix Network
8 hrs ago
The Globe and Mail
Novartis, GSK, Lilly sign multibillion-dollar deals to trade business units
Joe Jimenez, CEO of Swiss drug maker Novartis, gestures during an interview with Reuters at the company's headquarters in Basel in this March 19, 2014 file photo.
12 hrs ago
Investor's Business Daily
Novartis, Glaxo Swap Units; Lilly Buying Animal Biz
Novartis and Glaxo rose on the stock market today , while Lilly slipped a fraction.
16 hrs ago
With Big Pharma In Retreat, Ackman And Novartis Try A New Blueprint For Drug Companies
Yesterday in a move that returned attention to healthcare takeovers, Bill Ackman, CEO of the hedge fund Pershing Square Capital, announced a bold and unusual move by partnering with pharmaceutical company, Valeant Pharmaceuticals International plc's cancer-drug business for $14.5 billion and will sell most of its vaccine business to GSK for $7.1 ... (more)
20 hrs ago
Local Tech Wire
Novartis swaps businesses with GSK, plans to sell Holly Springs plant
Meanwhile, Novartis also plans to sell its huge vaccine production facility in Holly Springs in a separate deal.
The Huffington Post
Novartis Signs Multi-Billion Dollar Deals With GlaxoSmithKline, Lilly
Drug maker Novartis says it has signed several multibillion-dollar deals with GlaxoSmithKline and Lilly that will affect some 15,000 of its employees.
The Miami Herald
Novartis, GSK, Lilly in multibillion-dollar deals
Myles Chefetz does a tasting in the kitchen at Prime Fish with chef Todd Zimmer, April 14, 2014.
Mon Apr 21, 2014
PetMed Express Inc. Is Trying Harder to Push Sales
PetMed Express Inc. is a leading nationwide pet pharmacy and Vet-VIPPS accredited, delivering prescription and non-prescription medications, and pet supplies.
Clinical Trial Of Juno Therapeutics Cell Therapy Restarts
Earlier this month, a study of a much-watched cell therapy that genetically modifies patients' immune cells in order to attack tumors was stopped because the treatment may have caused the deaths of two patients.
Thu Apr 17, 2014
Last leader of violent animal rights group jailed for six years
Debbie Vincent was part of group that falsely accused Huntingdon Life Sciences workers of being paedophiles, posted sanitary towels claimed to be infected with AIDS, and desecrated the grave of the mother of a pharmaceutical company director Note: We do not store your email address but your IP address will be logged to prevent abuse of this ... (more)
Tue Apr 15, 2014
Novartis AG Ditches RNAi Development In Boston, Job Cuts Cited
Novartis isn't the only one hiring, others are hiring too! Check it out! Novartis is shuttering a large part of its once-ambitious RNAi research efforts in Boston, FierceBiotech has learned.
Cambridge Evening News
Stop Huntingdon Animal Cruelty (Shac) campaign against Huntingdon...
An animal rights protest group which aims to close down research firm Huntingdon Life Sciences was dubbed "quasi-terrorist" by an international pharmaceutical company seeking to protect staff against harassment.
Mon Apr 14, 2014
Nucleic Acids Research
Computational modeling identifies key gene regulatory interactions...
Here, we have identified key candidate regulators of phenobarbital -mediated mouse liver tumorigenesis, a well-characterized model of non-genotoxic carcinogenesis, by applying a new computational modeling approach to a comprehensive collection of in vivo gene expression studies.
Sun Apr 13, 2014
China Biotech In Review: WuXi Receives Award For cGMP...
BVCF, a China private equity growth investor specializing in healthcare and life sciences, has closed its third fund, BVCF III, L.P, with capital of $188 million .
Thu Apr 10, 2014
Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler Retires
Novartis announced earlier this week the appointment of Jeff George as division head of Alcon , effective May 1, 2014.
Wed Apr 09, 2014
Novartis names new division head at Alcon Labs in Fort Worth
Jeff George, who now heads the Novartis generic drugs division, Sandoz, which has its global headquarters in Holzkirchen, Germany, will succeed Kevin Buehler, who is retiring from Alcon, a eye pharmaceutical maker, after 30 years.
Novartis And MNM Provide 2 Million Anti-Malarial Drugs In Zambia
Novartis announced that two million units of its pediatric anti-malarial drug have been shipped to Zambia as part of ongoing efforts to eradicate the disease under its collaboration with Malaria No More and its campaign Power of One.
Seattle's Juno Therapeutics Pauses Trial After Patient Deaths
One of the most exciting new avenues in cancer research is the development of techniques to genetically re-engineer a patient's own immune cells to destroy tumors.
Tue Apr 08, 2014
FDA Grants Breakthrough Status Designation To Novartis AG' Meningitis B Vaccine
Novartis NVS +0.01% AG in Basel announced early this morning that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation - a rapid development track - for potential approval of BexseroA , their innovative vaccine against type B meningococcal meningitis.
Sun Apr 06, 2014
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
BASEL, SWITZERLAND , Apr. 07 /CSRwire/ - Novartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign.